Format

Send to

Choose Destination
Br J Cancer. 2016 May 10;114(10):1160-4. doi: 10.1038/bjc.2016.58. Epub 2016 Mar 17.

The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study.

Author information

1
Women's College Research Institute, Familial Breast Cancer Research, Toronto, ON M5G 1N8 Canada.
2
Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda MD 20892 USA.
3
International Hereditary Cancer Center, Pomeranian Medical University, 70-111 Szczecin, Poland.
4
Sunnybrook Regional Cancer Centre, Toronto, ON M4N3 M5 Canada.
5
Juravinksi Cancer Centre, Hamilton ON L8V 5C2 Canada.
6
Beth Israel Deaconess Medical Center, Cancer Risk and Prevention Program, Boston, MA 02215, USA.
7
Department of Preventive and Predictive Medicine, Fondazione IRCSS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
8
Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL 33647, USA.

Abstract

BACKGROUND:

Germline mutations in BRCA1 and BRCA2 increase the susceptibility to develop breast and ovarian cancers as well as increase the risk of some other cancers. Primary objective was to estimate the risk of leukaemia in BRCA1 and BRCA2 mutation carriers.

METHODS:

We followed 7243 women with a BRCA1 or a BRCA2 mutation for incident cases of leukaemia. We used the standardised incidence ratio (SIR) to estimate the relative risk of leukaemia, according to mutation and history of breast cancer.

RESULTS:

We identified five incident cases of leukaemia (two BRCA1, three BRCA2). All five women had a prior history of breast cancer and four had received chemotherapy. The mean time from breast cancer diagnosis to the development of leukaemia was 10.2 years (range 3-18 years). The SIR for BRCA1 carriers was 0.66 (95% CI: 0.11-2.19, P=0.61) and the SIR for BRCA2 carriers was 2.42 (95% CI: 0.61-6.58, P=0.17). The SIR was significantly higher than expected for women with a BRCA2 mutation and breast cancer (SIR=4.76, 95% CI:1.21-12.96, P=0.03), in particular for women who received chemotherapy (SIR=8.11, 2.06-22.07, P=0.007).

CONCLUSIONS:

We observed an increased risk of leukaemia in women with a BRCA2 mutation who receive chemotherapy for breast cancer.

PMID:
26986251
PMCID:
PMC4865972
DOI:
10.1038/bjc.2016.58
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center